749258-96-6

Usage

Uses

Used in Pharmaceutical Research:
3-Chloro-4-(trifluoromethyl)pyridazine is used as a reactant/reagent for the preparation of substituted pyridazinyl-and pyrimidinyl-quinolin-4-ylamine analogs. These analogs are essential for use in capsaicin VR1 receptor binding assays, which are crucial for studying the activity of compounds that target the capsaicin receptor, potentially leading to the development of new therapeutic agents.
Used in Organic Synthesis:
Due to its unique structural features, 3-chloro-4-(trifluoromethyl)pyridazine can be employed as an intermediate in the synthesis of a variety of organic compounds. Its reactivity allows for further functionalization and the formation of new chemical entities with potential applications in various fields, such as materials science, agrochemicals, and pharmaceuticals.

Upstream product

• 749258-95-5 5-(trifluoromethyl)-1H-pyridazin-6-one 
• 444689-44-5 ethyl 2-hydroxy-4-oxo-2-(trifluoromethyl)butanoate 

Downstream Products

• 1167417-13-1 4-(trifluoromethyl)pyridazin-3-amine 

Relevant academic research and scientific papers

COMPOUNDS USEFUL AS CSF1 MODULATORS

This invention relates to novel compounds and to pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as Colony Stimulating Factor 1 Receptor (cFMS) modulators (e.g. cFMS inhibitors). This invention also relates to processes for preparing the compounds, uses of the compounds in treatment and methods of treatment employing the compounds. Specifically, the invention relates to the use of the compounds for the treatment of cancer and autoimmune diseases.

IMIDAZO [1,2-B] PYRIDAZINE COMPOUNDS AS MODULATORS OF LIVER X RECEPTORS

This invention relates generally to imidazo[1,2-b] pyridazine-based modulators of Liver X receptors (LXRs) having formula (I) and related methods: Formula (I) wherein R2 is C6-C10 aryl or heteroaryl including 5-10 atoms, e

SUBSTITUTED AMINO HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN

The present invention provides compounds of formula I: in which: one of T1and T4 is N and the other is C; T2 and T3 are independently N or C(CH2)nR2; X, Y and Z are independently N or C(CH2)nR3; R1 is Ar1 or R1 is C1-6alkyl optionally substituted with one or two groups Ar1; Ar1 is an optionally substituted cyclohexyl, piperidinyl, piperazinyl, morpholinyl, adamantyl, phenyl, naphthyl, a six-membered heteroaromatic ring containing one, two or three nitrogen atoms, a five-membered heteroaromatic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one O or S atom being present, or a nine- or ten-membered bicyclic heteroaromatic ring in which phenyl or a six-membered heteroaromatic ring as defined above is fused to a six-or five-membered heteroaromatic ring as defined above; Ar is an optionally substituted phenyl, a six-membered heteroaromatic ring containing one, two or three nitrogen atoms or a five-membered heteroaromatic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one heteroatom being O or S, Ar being optionally substituted by one, two or three groups chosen from halogen, CF3, OCF3, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, nitro, cyano, isonitrile, hydroxy, C1-6alkoxy, C1-6alkylthio, -NR6R7, -CONR6R7, -COH, CO2H, C1-6alkoxycarbonyl, haloC1-6alkyl, hydroxyC1-6alkyl, aminoC1-6alkyl, C1-6alkylcarbonyl and a five-membered heteroaromatic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one heteroatom being O or S, optionally substituted by C1-6alkyl, halogen, amino, hydroxy or cyano; or a pharmaceutically acceptable salt thereof as a VR-1 ligand; pharmaceutical compositions comprising it; its use in therapy; use of it in the manufacture of a medicament to treat pain; and methods of treating subjects suffering from pain.